Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-PanTumor01
2023-507641-29-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in Nonhematologic neoplasms and prostate cancer (PCa), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate and PSA50 response rate. Planned start Jul 2024; status: authorised.
02
Drugs
patritumab deruxtecan
03
Conditions
Nonhematologic neoplasmsprostate cancer (PCa)
Beyond the preview
Go deeper on 2023-507641-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507641-29-00.